This combination therapy not only altered the profiles of Tregs, CD4+ T cells and CD8+ T cells but also influenced the cytokines (IL-12, IFN-γ, IL-10 and TGF-β1) at tumor sites. This evidence concerns the gene CD4 and neoplasm.